论文部分内容阅读
Hofmann及Popper证明熊去氧胆酸(UDCA)能明显降低6名慢性活动性肝炎病人的转氨酶(Lancet,Aug.15,1987.398页)。他们也发现UDCA对2名原发性硬化性胆管炎病人及6名原发性胆汁性肝硬化病人也有疗效。这6名病人在治疗过程中,其内源性胆酸清除率得到改善。停止治疗后,转氨酶再次升高,但没有达到最初水平。Fisher及Paradine报道了10名原发性胆汁性肝硬化妇女的治疗情况。 1984年本文作者U Leuschner(Lancet,8月29日,1987,508页)开始进行了一项关于UDCA治疗原发性胆汁性肝硬化、原发性硬化性胆管炎及慢性活动性肝炎病人的前瞻性双盲研究,同时也进行了标准的实验室检验及
Hofmann and Popper demonstrated that ursodeoxycholic acid (UDCA) significantly reduced transaminases in six chronic active hepatitis patients (Lancet, Aug. 15, p. They also found that UDCA was also effective in 2 patients with primary sclerosing cholangitis and in 6 patients with primary biliary cirrhosis. The six patients had improved endogenous bile acid clearance during treatment. After stopping treatment, aminotransferases increased again, but did not reach the initial level. Fisher and Paradine reported the treatment of 10 women with primary biliary cirrhosis. In 1984, author U Leuschner (Lancet, August 29, 1987, p. 508) started a prospective review of UDCA in patients with primary biliary cirrhosis, primary sclerosing cholangitis and chronic active hepatitis Double-blind study, but also conducted a standard laboratory tests and